IMMUCELL CORP /DE/·4

Apr 16, 3:59 PM ET

Basse Gloria F 4

Research Summary

AI-generated summary

Updated

IMMUCELL (ICCC) Director Gloria Basse Receives Stock Option Award

What Happened
Gloria F. Basse, a director of Immucell Corp (ICCC), was granted 11,933 stock options on April 15, 2026. The grant shows an acquisition price of $0.00 (i.e., options awarded, not purchased) and is reported as a derivative award to compensate board service. The options themselves were not exercised or sold — this filing reports the grant only.

Key Details

  • Transaction date: 2026-04-15; Form 4 filed 2026-04-16.
  • Grant: 11,933 stock options, acquisition price reported as $0.00 (derivative award).
  • Vesting schedule (footnote): 3,977 options vest on April 15, 2027; 3,977 on April 15, 2028; and 3,979 on April 15, 2029.
  • Purpose: Options granted to compensate directors for services on the issuer’s board (per filing remarks).
  • Shares owned after the transaction: not specified in the excerpt provided.
  • Filing timeliness: reported the day after the grant; no late-filing flag noted in the provided information.

Context
This is a standard director compensation award (options), not a purchase or sale of underlying shares. For retail investors, such grants are common and are meant to align director interests with shareholders; they do not represent immediate insider buying/selling pressure unless and until options are exercised and shares are sold.